Importantly, post-hoc analysis of the CRYSTAL and FIRE-3 trials, suggests an association between PTL and response to anti-EGFR therapy [83], as right-sided KRAS wild-type CRC did not seem to benefit from cetuximab treatment. Here, EGFR is linked to colorectal carcinoma.